Student at Shiraz University of Medical Sciences, clinical pharmacy student, pharmaceutical research center
Landiolol is an ultra-short-acting, selective β1-adrenergic receptor blocker that was origi- nally approved in Japan for the treatment of intraoperative tachyarrhythmias. It has gained attention for its use in the management of tachyarrhythmias and perioperative tachycardia, especially atrial fib- rillation for both cardiac and non-cardiac surgeries. It can be the ideal agent for heart rate control due to its high β1-selectivity, potent negative chronotropic effect, a limited negative inotropic potential, and an ultrashort elimination half-life (around 4 min); moreover, it may have a potential therapeutic effects for sepsis and pediatric patients. Landiolol seems to be superior to other short-acting and selective beta-blockers such as esmolol.
PharmD;PhD candidate . Interested in drug nanoencapsulation and herbal pharmaceuticals
7mo👌👌